Free Trial

GENMAB A/S/S (GMXAY) News Today

GENMAB A/S/S logo
$20.31 +0.22 (+1.10%)
(As of 12/20/2024 ET)
RBC Capital Keeps Their Buy Rating on Genmab A/S (0MGB)
Genmab shares reiterate Buy rating on FDA approval
Strong Financials and Pipeline Promise Affirm Buy Rating for Genmab A/S
Decoding 10 Analyst Evaluations For Genmab
Here's what to expect from Genmab A-S (spons ADRs)'s earnings
Decoding 9 Analyst Evaluations For Genmab
Earnings Preview For Genmab
Earnings Outlook For Genmab
Get GENMAB A/S/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for GMXAY and its competitors with MarketBeat's FREE daily newsletter.

The #1 Coin for November 2024 (Ad)

Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…

You can get access to the report by clicking here now…

GMXAY Media Mentions By Week

GMXAY Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

GMXAY
News Sentiment

0.00

0.60

Average
Medical
News Sentiment

GMXAY News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

GMXAY Articles
This Week

0

0

GMXAY Articles
Average Week

Get GENMAB A/S/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for GMXAY and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (OTCMKTS:GMXAY) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners